Seung Hyeun Lee1, Joo Won Min2, Ji Sung Lee3, Chul Hwan Kim4, Young Do Yoo5, Eun Joo Lee6, Kyung Hoon Min6, Gyu Young Hur6, Seung Heon Lee6, Sung Yong Lee6, Je Hyeong Kim6, Sang Yeub Lee6, Chol Shin6, Jae Jeong Shim6, Kyung Ho Kang6, Kwang Ho In7. 1. Department of Internal Medicine, KEPCO Medical Center, Seoul, South Korea. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Myongji Hospital, Ilsan, South Korea. 3. Biostatistical Consulting Unit, Sunchunhyang University Medical Center, Seoul, South Korea. 4. Department of Pathology, College of Medicine, Korea University, Seoul, South Korea. 5. Laboratory of Molecular Cell Biology, Graduate School of Medicine, Korea University, Seoul, South Korea. 6. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea. 7. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea. Electronic address: khin@kumc.or.kr.
Abstract
OBJECTIVES: Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. MATERIALS AND METHODS: Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n=110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. RESULTS: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95% CI: 1.39-9.97) and overall survival (HR=4.21, 95% CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. CONCLUSIONS: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.
OBJECTIVES:Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays an important role in intracellular reactive oxygen species generation. Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro. However, little information is available on its clinical implications. We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection. MATERIALS AND METHODS:Romo1 protein expressions were evaluated immunohistochemically in resected tumor specimens. Survival analyses for overall population (n=110) and early-stage patients (n=97) were performed according to clinical parameters including level of Romo1 expression. RESULTS: Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21). Stronger associations were observed between Romo1 expression and disease-free survival (HR=3.69, 95% CI: 1.39-9.97) and overall survival (HR=4.21, 95% CI: 1.12-14.67) in stage I and II patients than in the overall population. Romo1 expression was not associated with any clinical parameter including age, gender, smoking status, stage, differentiation, or tumor histology. CONCLUSIONS: Increased Romo1 expression in surgically resected NSCLC was found to be significantly associated with early recurrence and poor survival. Romo1 overexpression could be a potential adverse prognostic marker in this setting.
Authors: Hong Jun Kim; Min Jee Jo; Bo Ram Kim; Jung Lim Kim; Yoon A Jeong; Yoo Jin Na; Seong Hye Park; Suk-Young Lee; Dae-Hee Lee; Hye Seung Lee; Baek-Hui Kim; Sun Il Lee; Byung Wook Min; Young Do Yoo; Sang Cheul Oh Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240
Authors: Seung Hyeun Lee; Myung Jae Park; Sue In Choi; Eun Joo Lee; Sang Yeub Lee; Kwang Ho In Journal: Medicine (Baltimore) Date: 2017-01 Impact factor: 1.889
Authors: Seung Hyeun Lee; Sue In Choi; Ji Sung Lee; Chul Hwan Kim; Won Jai Jung; Eun Joo Lee; Kyung Hoon Min; Gyu Young Hur; Seung Heon Lee; Sung Yong Lee; Je Hyeong Kim; Sang Yeub Lee; Chol Shin; Jae Jeong Shim; Kyung Ho Kang; Kwang Ho In Journal: Cancer Res Treat Date: 2016-05-18 Impact factor: 4.679
Authors: Hong Jun Kim; Min Jee Jo; Bo Ram Kim; Jung Lim Kim; Yoon A Jeong; Yoo Jin Na; Seong Hye Park; Suk-Young Lee; Dae-Hee Lee; Baek-Hui Kim; Young Do Yoo; Sang Cheul Oh Journal: Onco Targets Ther Date: 2018-07-23 Impact factor: 4.147